These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15148857)

  • 21. Intelligence in mild atypical phenylketonuria.
    Costello PM; Beasley MG; Tillotson SL; Smith I
    Eur J Pediatr; 1994 Apr; 153(4):260-3. PubMed ID: 8194559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Children and adolescents with phenylketonuria display fluctuations in their blood phenylalanine levels.
    Feldmann R; Schallert M; Nguyen T; Och U; Rutsch F; Weglage J
    Acta Paediatr; 2019 Mar; 108(3):541-543. PubMed ID: 30047169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes of blood phenylalanine concentrations in children with classical phenylketonuria.
    Hartnett C; Salvarinova-Zivkovic R; Yap-Todos E; Cheng B; Giezen A; Horvath G; Lillquist Y; Vallance H; Stockler-Ipsiroglu S
    Mol Genet Metab; 2013 Apr; 108(4):255-8. PubMed ID: 23465864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.
    Jahja R; Huijbregts SC; de Sonneville LM; van der Meere JJ; Bosch AM; Hollak CE; Rubio-Gozalbo ME; Brouwers MC; Hofstede FC; de Vries MC; Janssen MC; van der Ploeg AT; Langendonk JG; van Spronsen FJ
    Mol Genet Metab; 2013; 110 Suppl():S57-61. PubMed ID: 24183792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis.
    Waisbren SE; Noel K; Fahrbach K; Cella C; Frame D; Dorenbaum A; Levy H
    Mol Genet Metab; 2007; 92(1-2):63-70. PubMed ID: 17591452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adult patients with well-controlled phenylketonuria tolerate incidental additional intake of phenylalanine.
    van Rijn M; Hoeksma M; Sauer PJ; Modderman P; Reijngoud DJ; van Spronsen FJ
    Ann Nutr Metab; 2011; 58(2):94-100. PubMed ID: 21474926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How practical are recommendations for dietary control in phenylketonuria?
    Walter JH; White FJ; Hall SK; MacDonald A; Rylance G; Boneh A; Francis DE; Shortland GJ; Schmidt M; Vail A
    Lancet; 2002 Jul; 360(9326):55-7. PubMed ID: 12114043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective, observational data collection of the treatment of phenylketonuria in the UK, and associated clinical and health outcomes.
    Macdonald A; Nanuwa K; Parkes L; Nathan M; Chauhan D
    Curr Med Res Opin; 2011 Jun; 27(6):1211-22. PubMed ID: 21504301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of a camp experience on phenylalanine levels, knowledge, attitudes, and health beliefs relevant to nutrition management of phenylketonuria in adolescent girls.
    Singh RH; Kable JA; Guerrero NV; Sullivan KM; Elsas LJ
    J Am Diet Assoc; 2000 Jul; 100(7):797-803. PubMed ID: 10916518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
    Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence to diet and quality of life in patients with phenylketonuria.
    Cotugno G; Nicolò R; Cappelletti S; Goffredo BM; Dionisi Vici C; Di Ciommo V
    Acta Paediatr; 2011 Aug; 100(8):1144-9. PubMed ID: 21342250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive functioning in adults with phenylketonuria: results of a long term study.
    Weglage J; Fromm J; van Teeffelen-Heithoff A; Möller HE; Koletzko B; Marquardt T; Rutsch F; Feldmann R
    Mol Genet Metab; 2013; 110 Suppl():S44-8. PubMed ID: 24071437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of patients treated for phenylketonuria (PKU). Results from the Prague PKU Center.
    Cechák P; Hejcmanová L; Rupp A
    Eur J Pediatr; 1996 Jul; 155 Suppl 1():S59-63. PubMed ID: 8828612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU.
    Daly A; Evans S; Chahal S; Santra S; Pinto A; Jackson R; Gingell C; Rocha J; Van Spronsen FJ; MacDonald A
    Orphanet J Rare Dis; 2019 Feb; 14(1):44. PubMed ID: 30770754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenylalanine metabolites as indicators of dietary compliance in children with phenylketonuria.
    Michals K; Lopus M; Matalon R
    Biochem Med Metab Biol; 1988 Feb; 39(1):18-23. PubMed ID: 3355711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive effect of a simplified diet on blood phenylalanine control in different phenylketonuria variants, characterized by newborn BH4 loading test and PAH analysis.
    Zimmermann M; Jacobs P; Fingerhut R; Torresani T; Thöny B; Blau N; Baumgartner MR; Rohrbach M
    Mol Genet Metab; 2012 Jul; 106(3):264-8. PubMed ID: 22607939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level.
    Schmidt E; Rupp A; Burgard P; Pietz J; Weglage J; de Sonneville L
    J Clin Exp Neuropsychol; 1994 Oct; 16(5):681-8. PubMed ID: 7836491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimising growth in phenylketonuria: current state of the clinical evidence base.
    Dokoupil K; Gokmen-Ozel H; Lammardo AM; Motzfeldt K; Robert M; Rocha JC; van Rijn M; Ahring K; Bélanger-Quintana A; MacDonald A
    Clin Nutr; 2012 Feb; 31(1):16-21. PubMed ID: 21959353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.
    Viau KS; Wengreen HJ; Ernst SL; Cantor NL; Furtado LV; Longo N
    J Inherit Metab Dis; 2011 Aug; 34(4):963-71. PubMed ID: 21556836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria.
    Huijbregts S; de Sonneville L; Licht R; Sergeant J; van Spronsen F
    Dev Neuropsychol; 2002; 22(2):481-99. PubMed ID: 12537335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.